Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival
Arch. endocrinol. metab. (Online)
;
67(6): e000654, Mar.-Apr. 2023. tab
Artigo
em Inglês
|
LILACS-Express
| LILACS
| ID: biblio-1447274
ABSTRACT
ABSTRACT Objective:
To evaluate the association between the patients' characteristics and the development of endocrine toxicity and to assess the association between endocrine-related adverse effects (ERAE) development and mortality. Subjects andmethods:
A retrospective observational study was conducted in 98 patients submitted to immunotherapy in our centre since its introduction in 2015 until March 2021. We excluded patients for which data regarding the corticotroph axis evaluation was missing. We used linear and logistic regression models to address our aims.Results:
We observed a significant negative association between ERAE development and death (OR 0.32; p = 0.028). We detected no associations between ERAE and the following characteristics age at immune checkpoint inhibitors (ICI) initiation, sex, diabetes mellitus, medical history, immunotherapy duration and ICI type.Conclusion:
The development of an ERAE may be associated with a better overall survival rate in advanced oncologic disease, supporting the role of an unleashed immune system response to malignant cells.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Idioma:
Inglês
Revista:
Arch. endocrinol. metab. (Online)
Assunto da revista:
Endocrinologia
/
Metabolismo
Ano de publicação:
2023
Tipo de documento:
Artigo
País de afiliação:
Portugal
Instituição/País de afiliação:
Centro Hospitalar Universitário de São João/PT
/
Hospital Central do Funchal/PT
Similares
MEDLINE
...
LILACS
LIS